June 2006 in “American Journal of Epidemiology” Higher BMI is linked to a lower risk of non-aggressive prostate cancer and a higher risk of aggressive prostate cancer.
March 2018 in “European Urology Supplements” Patients follow treatment well, but many change medicines; good information helps compliance.
April 2017 in “The Journal of Urology” Finasteride before TURP reduces blood loss and improves early postoperative quality of life.
May 2016 in “The Journal of Sexual Medicine” October 2015 in “Elsevier eBooks” Finasteride helps hair growth and prostate issues but may cause sexual side effects and increase tumor risk.
April 2010 in “The Journal of Urology” Hair loss, prostate size, and urinary issues are related due to androgen effects.
1707 citations,
December 2003 in “The New England Journal of Medicine” Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.
1054 citations,
February 1998 in “The New England Journal of Medicine” Finasteride reduces urinary issues and surgery need in men with enlarged prostates by over 50%.
855 citations,
June 2009 in “The Journal of Clinical Endocrinology & Metabolism” The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.
728 citations,
August 1996 in “The New England Journal of Medicine” Terazosin and finasteride effectively treat BPH, but combining them adds no extra benefit.
581 citations,
October 1998 in “Journal of The American Academy of Dermatology” Finasteride safely and effectively treats male pattern hair loss, but may cause reversible sexual issues and harm male fetuses.
522 citations,
January 2001 in “Cancer investigation” Doxil is an effective, modified chemotherapy drug with a unique toxicity profile and shows promise in treating certain cancers.
506 citations,
March 2005 in “The Journal of Clinical Endocrinology and Metabolism” Testosterone therapy improves physical function, strength, and body composition in older men with low testosterone levels.
403 citations,
November 2005 in “Journal of Endocrinology” Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.
402 citations,
August 2011 in “Cancer research” Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.
238 citations,
March 2013 in “Development” Fat cells help recruit healing cells and build skin structure during wound healing.
232 citations,
January 2013 in “Nature Cell Biology” Understanding where cancer cells come from helps create better prevention and treatment methods.
225 citations,
July 2007 in “The Journal of Sexual Medicine” Knowing about finasteride's sexual side effects increases reported dysfunction.
218 citations,
December 2011 in “Advances in Urology” The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.
212 citations,
September 2008 in “Journal of The American Academy of Dermatology” Minoxidil and finasteride treat hair loss in men, while minoxidil treats hair loss in women.
211 citations,
November 1990 in “The Journal of Steroid Biochemistry and Molecular Biology” Finasteride effectively treats BPH, but needs more trials to understand potential.
204 citations,
February 2000 in “Current Medicinal Chemistry” Antiandrogens like flutamide are effective in treating conditions like prostate cancer and hair loss, but there's a need for more potent versions. Understanding their structure can help develop better treatments.
203 citations,
December 2004 in “Journal of The American Academy of Dermatology” Early diagnosis and treatment, using finasteride, minoxidil, or hair transplantation, improves hair loss outcomes.
198 citations,
October 2011 in “Journal der Deutschen Dermatologischen Gesellschaft” Use minoxidil for hair loss; finasteride and dutasteride for men, dutasteride for women.
182 citations,
November 2017 in “Molecular Aspects of Medicine” The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.
151 citations,
May 2014 in “American Journal of Clinical Dermatology” Effective treatments for male pattern baldness include oral finasteride and topical minoxidil, while topical minoxidil is best for female pattern baldness.
151 citations,
August 2010 in “British Journal of Dermatology” Guidelines for diagnosing common hair loss include detailed history, clinical examination, and various diagnostic techniques.
147 citations,
June 2011 in “New England journal of medicine/The New England journal of medicine” 5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
144 citations,
November 2020 in “Frontiers in immunology” Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.
125 citations,
January 1999 in “Drugs” Finasteride effectively treats baldness but may cause sexual side effects.